There is an ongoing prospective cross-sectional partially blinded multicenter clinical trial assessing the added value of PSMA PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer [110]. This evidence concerns the gene FOLH1 and prostate carcinoma.